Karyopharm Therapeutics vs Standard BioTools
KPTI and LAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KPTI and LAB compare
Standard BioTools is the larger company, worth 278 times as much as Karyopharm Therapeutics ($252M against $907K).
Karyopharm Therapeutics grew revenue faster over the last twelve months (6.8% versus −4.8% for Standard BioTools).
Standard BioTools keeps more of each dollar of sales as profit, with a net margin of 100% compared with −153% at Karyopharm Therapeutics.
Standard BioTools scores higher on the StockData Score (12 against 1 for Karyopharm Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KPTI | LAB |
|---|---|---|
| Size and price | ||
| Market cap | $907K | $252M |
| Share price | $0.040 | $0.643 |
| Change, 1 year | −99.2% | −45.0% |
| Change, 5 years | −100.0% | −85.7% |
| Beta (5Y) | 1.68 | 1.53 |
| Employees | 228 | 389 |
| StockData Score | ||
| Total score | 1 | 12 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 2.9× |
| P/S | 0.0× (better) | 3.0× |
| P/B | – | 0.5× |
| FCF yield | – | −32.7% |
| Fair value | – | $4.90 |
| Margin of safety | – | 86.9% |
| Growth | ||
| Revenue growth (TTM) | 6.8% (better) | −4.8% |
| Revenue growth, 5Y average | 6.2% (better) | −9.2% |
| Profitability | ||
| Gross margin | – | 50.5% |
| Operating margin | −56.2% (better) | −113% |
| Net margin | −153% | 100% (better) |
| FCF margin | – | −97.6% |
| Return on equity | – | 17.6% |
| Return on invested capital | – | −60.8% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −1.7× | – |
| Current ratio | 0.79 | 9.10 (better) |
| Altman Z-score | −24.68 | −0.34 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.1% | 75.4% |
| Held by insiders | 3.7% | 70.2% |
| Insider net buying, 12 months | −$351K | $550K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 37.7% | 1.9% |
Go deeper
- KPTI stock overview
- KPTI income statement
- KPTI valuation and score
- LAB stock overview
- LAB income statement
- LAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.